Insider Selling: DuPont de Nemours (NYSE:DD) CEO Sells $349,307.65 in Stock

Key Points

• DuPont CEO Lori Koch sold 2,311 shares for $349,307.65, reducing her stake by 1.96%; she directly held 115,715 shares after the transaction.
• DuPont reported quarterly EPS of $2.09, beating the $1.87 consensus, while revenue of $1.87 billion also exceeded estimates and rose 4.1% year over year.
• Analysts’ consensus rating was Moderate Buy, with an average price target of $165.88. The company also declared a $0.60 quarterly dividend per share.

DuPont de Nemours, Inc. (NYSE:DD - Get Free Report) CEO Lori Koch sold 2,311 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $151.15, for a total transaction of $349,307.65. Following the sale, the chief executive officer directly owned 115,715 shares of the company's stock, valued at $17,490,322.25. The trade was a 1.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

DuPont de Nemours Trading Up 5.7%

DuPont de Nemours stock traded up $8.41 during trading hours on Monday, reaching $154.93. The stock had a trading volume of 1,101,344 shares, compared to its average volume of 1,350,165. The stock has a market cap of $20.53 billion, a PE ratio of 69.47, a PEG ratio of 1.27 and a beta of 1.06. DuPont de Nemours, Inc. has a 52 week low of $111.15 and a 52 week high of $157.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.36 and a quick ratio of 1.74. The company has a fifty day simple moving average of $133.21 and a 200-day simple moving average of $138.80.

DuPont de Nemours (NYSE:DD - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The basic materials company reported $2.09 EPS for the quarter, beating the consensus estimate of $1.87 by $0.22. The firm had revenue of $1.87 billion during the quarter, compared to the consensus estimate of $1.84 billion. DuPont de Nemours had a net margin of 4.26% and a return on equity of 6.85%. The company's quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.09 earnings per share. Analysts forecast that DuPont de Nemours, Inc. will post 7.51 EPS for the current fiscal year.

DuPont de Nemours Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 30th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date is Monday, November 30th. DuPont de Nemours's payout ratio is currently 107.62%.

Analysts Set New Price Targets

DD has been the subject of several research analyst reports. Zacks Research cut DuPont de Nemours from a "strong-buy" rating to a "hold" rating in a report on Friday, July 17th. Citigroup raised their target price on DuPont de Nemours from $162.00 to $176.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. Weiss Ratings restated a "sell (d+)" rating on shares of DuPont de Nemours in a research report on Friday, October 30th. JPMorgan Chase & Co. cut DuPont de Nemours from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $172.00 to $145.00 in a research note on Friday, October 9th. Finally, Royal Bank Of Canada increased their price objective on DuPont de Nemours from $160.00 to $173.00 and gave the stock an "outperform" rating in a report on Thursday. Twelve research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DuPont de Nemours currently has a consensus rating of "Moderate Buy" and a consensus price target of $165.88.

Institutional Investors Weigh In On DuPont de Nemours

Hedge funds have recently bought and sold shares of the business. Physician Wealth Advisors Inc. grew its stake in shares of DuPont de Nemours by 223.1% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 210 shares of the basic materials company's stock worth $27,000 after buying an additional 145 shares during the last quarter. Elevation Wealth Partners LLC raised its holdings in DuPont de Nemours by 168.5% in the second quarter. Elevation Wealth Partners LLC now owns 239 shares of the basic materials company's stock worth $32,000 after buying an additional 150 shares during the last quarter. DHJJ Financial Advisors Ltd. raised its holdings in DuPont de Nemours by 150.0% in the third quarter. DHJJ Financial Advisors Ltd. now owns 250 shares of the basic materials company's stock worth $32,000 after buying an additional 150 shares during the last quarter. Bangor Savings Bank bought a new position in shares of DuPont de Nemours in the third quarter worth approximately $36,000. Finally, Compass Wealth Management LLC bought a new position in shares of DuPont de Nemours in the third quarter worth approximately $39,000. Institutional investors own 73.96% of the company's stock.

About DuPont de Nemours

DuPont de Nemours is a science and materials company that develops products for customers in markets including construction, healthcare, water treatment, transportation and worker safety. Its offerings include protective materials such as Kevlar, Nomex and Tyvek, as well as Corian surface materials and technologies used in water purification and separation.

The company traces its roots to 1802, when E. I. du Pont established a gunpowder mill in Delaware. Over time, DuPont expanded into a broad range of chemical and advanced-materials businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.